The acquisition presents exciting opportunities for accelerated growth as it expands Rosemont's portfolio and grants access to new and attractive product areas, along with a pipeline of upcoming products
Rosemont Pharmaceuticals acquires Lucis Pharma. (Credit: Rosemont Pharmaceuticals Limited)
Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma, a specialist pharmaceutical business in the UK, for an undisclosed sum.
This acquisition presents exciting opportunities for accelerated growth as it expands Rosemont’s portfolio and grants access to new and attractive product areas, along with a pipeline of upcoming products.
Lucis Pharma, established in 2012, has emerged as a prominent provider in the development and licensing of exclusive and groundbreaking medicines. With a diverse range of over a dozen products spanning various therapeutic areas, Lucis has built a robust portfolio that caters to the increasing demand for liquid medicines. Furthermore, their ongoing innovative developments ensure a continuous supply of life-saving pharmaceuticals to both domestic and international markets.
By acquiring Lucis Pharma Ltd, Rosemont aims to enhance its existing portfolio and enter the unit dose/sachet market through the pipeline products. Additionally, the recent product launches by Lucis in 2021/22 will further contribute to the growth of Rosemont’s business.
Rosemont CEO Howard Taylor said: “As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets.
“We will continue creating innovative solutions that meet the needs of dysphagic patients and establish best practice for their care”.
With a legacy spanning more than five decades, Rosemont Pharmaceuticals brings a wealth of experience in developing novel, prescription-based oral liquid medicines. Renowned for its expertise in this specialized field, Rosemont boasts one of the most extensive product portfolios globally, consisting of over 130 oral liquid medicines. These medicines cater to a wide range of therapeutic areas, including cardiac health, endocrinology, and pain management, specifically tailored for patients facing challenges with swallowing.
Rosemont’s commitment to addressing the needs of patients with swallowing difficulties underscores its dedication to enhancing accessibility and ensuring effective treatment options. By offering a diverse range of oral liquid medicines, Rosemont provides vital support to individuals who encounter difficulties with traditional solid dosage forms.
Drawing upon their extensive experience and broad product range, Rosemont continues to play a pivotal role in delivering innovative solutions that improve patient outcomes and enhance the quality of life for those requiring specialised oral liquid medications.